Referencias
Artículos principales
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-77.Texto completo Resumen
National Cancer Comprehensive Network. NCCN guidelines: acute myeloid leukemia [internet publication].Texto completo
Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jun;31(6):697-712.Texto completo Resumen
Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 Aug 11;4(15):3528-49.Texto completo Resumen
Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-43.Texto completo Resumen
Artículos de referencia
1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.Texto completo Resumen
2. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-28.Texto completo Resumen
3. Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015 May 21;125(21):3246-52.Texto completo Resumen
4. Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? Cells. 2020 Oct 17;9(10):2310.Texto completo Resumen
5. National Cancer Institute. Cancer stat facts: leukemia - acute myeloid leukemia (AML) [internet publication].Texto completo
6. Cancer Research UK. Acute myeloid leukaemia (AML) incidence statistics. Sep 2021 [internet publication].Texto completo
7. Leone G, Pagano L, Ben-Yehuda D, et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007 Oct;92(10):1389-98.Texto completo Resumen
8. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, et al. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia. 2002 Nov;16(11):2177-84. Resumen
9. Bizzozero D, Johnson K, Ciocco A. Radiation-related leukemia in Hiroshima and Nagasaki 1946-1964. I. Distribution, incidence and appearance time. N Engl J Med. 1966;274:1095-1101. Resumen
10. Jacobs A. Benzene and leukemia. Br J Haematol. 1989;72:119-122. Resumen
11. Kayser S, Döhner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011 Feb 17;117(7):2137-45.Texto completo Resumen
12. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991 Dec 12;325(24):1682-7. Resumen
13. Maciejewski JP, Risitano A, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002 May 1;99(9):3129-35.Texto completo Resumen
14. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999 May 27;340(21):1649-60. Resumen
15. Berk PD, Wasserman LR, Fruchtman SM, et al. Treatment of polycythemia vera: a summary of trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia, PA: WB Saunders; 1995:166-94.
16. Silverstein MN, Brown AL Jr, Linman JW. Idiopathic myeloid metaplasia. Its evolution into acute leukemia. Arch Intern Med. 1973 Nov;132(5):709-12. Resumen
17. Rosenthal S, Canellos GP, DeVita VT Jr, et al. Characteristics of blast crisis in chronic granulocytic leukemia. Blood. 1977 May;49(5):705-14. Resumen
18. Alter BP. Fanconi's anemia and malignancies. Am J Hematol. 1996 Oct;53(2):99-110. Resumen
19. Bloom G, Warner S, Gerald P, Diamond JK. Chromosomal abnormalities in constitutional aplastic anemia. N Engl J Med. 1966 Jan 6;274(1):8-14. Resumen
20. D'Andrea AD, Dahl N, Guinan EC, et al. Marrow failure. Hematology Am Soc Hematol Educ Program. 2002:58-72.Texto completo Resumen
21. Gilman PA, Jackson DP, Guild HG. Congenital agranulocytosis, prolonged survival and terminal acute leukemia. Blood. 1970 Nov;36(5):576-85. Resumen
22. Rosen RB, Kang SJ. Congenital agranulocytosis terminating in acute myelomonocytic leukemia. J Pediatr. 1979 Mar;94(3):406-8. Resumen
23. Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure syndromes. Br J Haematol. 2000 Oct;111(1):30-42. Resumen
24. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-77.Texto completo Resumen
25. Taub JW, Berman JN, Hitzler JK, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017 Jun 22;129(25):3304-13.Texto completo Resumen
26. Jalbut MM, Sohani AR, Dal Cin P, et al. Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. Leuk Res Rep. 2015;4(1):28-30.Texto completo Resumen
27. Herold T, Metzeler KH, Vosberg S, et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014 Aug 21;124(8):1304-11.Texto completo Resumen
28. Forestier E, Israeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008 Feb 1;111(3):1575-83. Resumen
29. Fircanis S, Merriam P, Khan N, et al. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol. 2014 Aug;89(8):E125-32.Texto completo Resumen
30. Colamesta V, D'Aguanno S, Breccia M, et al. Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults? Crit Rev Oncol Hematol. 2016 Mar;99:376-88. Resumen
31. Mele A, Szklo M, Visani G, et al. Hair dye use and other risk factors for leukemia and pre-leukemia: a case control study. Italian Leukemia Study Group. Am J Epidemiol. 1994 Mar 15;139(6):609-19. Resumen
32. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J Natl Cancer Inst. 1977 Mar;58(3):525-47. Resumen
33. Towle KM, Grespin ME, Monnot AD. Personal use of hair dyes and risk of leukemia: a systematic literature review and meta-analysis. Cancer Med. 2017 Oct;6(10):2471-86.Texto completo Resumen
34. Rota M, Porta L, Pelucchi C, et al. Alcohol drinking and risk of leukemia-a systematic review and meta-analysis of the dose-risk relation. Cancer Epidemiol. 2014 Aug;38(4):339-45. Resumen
35. Blair A, Zahm SH, Pearce NE, et al. Clues to cancer etiology from studies of farmers. Scand J Work Environ Health. 1992 Aug;18(4):209-15. Resumen
36. Metayer C, Johnson ES, Rice JC. Nested case-control study of tumors of the hemopoietic and lymphatic systems among workers in the meat industry. Am J Epidemiol. 1998 Apr 15;147(8):727-38.Texto completo Resumen
37. Bethwaite P, McLean D, Kennedy J, et al. Adult-onset acute leukemia and employment in the meat industry: a New Zealand case-control study. Cancer Causes Control. 2001 Sep;12(7):635-43. Resumen
38. Pedersen-Bjeregaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007:392-397.Texto completo Resumen
39. Youn BS, Mantel C, Broxmeyer HE. Chemokines, chemokine receptors and hematopoiesis. Immunol Rev. 2000 Oct;177:150-74. Resumen
40. Anderlini P, Luna M, Kantarjian HM, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplatic syndromes. Leukemia. 1996 Apr;10(4):600-8. Resumen
41. Seymour JF, Pierce SA, Kantarjian H, et al. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994 May;8(5):823-6. Resumen
42. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969 Oct;71(4):747-52. Resumen
43. Smith ML, Cavenagh JD, Lister TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004 Dec 2;351(23):2403-7.Texto completo Resumen
44. Bader J, Miller R. Neurofibromatosis and childhood leukemia. J Pediatr. 1978 Jun;92(6):925-9. Resumen
45. Shimizu Y, Schull WJ, Kato H. Cancer risk among atomic bomb survivors. The RERF Life Span Study. Radiation Effects Research Foundation. JAMA. 1990 Aug 1;264(5):601-4. Resumen
46. Guru Murthy GS, Abedin S. Myeloid malignancies after treatment for solid tumours. Best Pract Res Clin Haematol. 2019 Mar;32(1):40-6. Resumen
47. Rinsky RA, Smith AB, Hornung R, et al. Benzene and leukemia. An epidemiologic risk assessment. N Engl J Med. 1987 Apr 23;316(17):1044-50. Resumen
48. Kok PW, Ong CN. Blood and urinary benzene determined by headspace gas chromatography with photoionization detection: application in biological monitoring or low-level nonoccupational exposure. Int Arch Occup Environ Health. 1994;66(3):195-201. Resumen
49. Hayes RB, Yin SN, Doemeci M, et al. Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group. J Natl Cancer Inst. 1997 Jul 16;89(14):1065-71.Texto completo Resumen
50. Lan Q, Zhang L, Li G, et al. Hematotoxicity in workers exposed to low levels of benzene. Science. 2004 Dec 3;306(5702):1774-6.Texto completo Resumen
51. National Cancer Comprehensive Network. NCCN guidelines: acute myeloid leukemia [internet publication].Texto completo
52. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011 May 12;364(19):1844-54.Texto completo Resumen
53. Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 Nov;86(5):1327-30. Resumen
54. Arber DA, Borowitz MJ, Cessna M, et al. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. Arch Pathol Lab Med. 2017 Oct;141(10):1342-93.Texto completo Resumen
55. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions [internet publication].Texto completo
56. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016 Jan;172(2):187-207.Texto completo Resumen
57. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Mar;47(3):337-41. Resumen
58. Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jun;31(6):697-712.Texto completo Resumen
59. Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 Aug 11;4(15):3528-49.Texto completo Resumen
60. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1249-59.Texto completo Resumen
61. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013 Sep 20;31(27):3360-8. Resumen
62. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010 Feb 1;28(4):586-95.Texto completo Resumen
63. Lee JH, Joo YD, Kim H, et al; Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011 Oct 6;118(14):3832-41. Resumen
64. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011 Mar 17;364(11):1027-36.Texto completo Resumen
65. Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol. 2014 Jan 20;32(3):219-28. Resumen
66. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009 Nov 10;27(32):5397-403.Texto completo Resumen
67. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 Jun 18;125(25):3878-85.Texto completo Resumen
68. Luskin MR, Lee JW, Fernandez HF, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551-8.Texto completo Resumen
69. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001 Sep 1;98(5):1302-11. Resumen
70. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011 Mar;152(5):524-42.Texto completo Resumen
71. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6;331(14):896-903.Texto completo Resumen
72. Sperr WR, Piribauer M, Wimazal F, et al. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Clin Cancer Res. 2004 Jun 15;10(12 pt 1):3965-71.Texto completo Resumen
73. Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011 Nov;155(3):366-76. Resumen
74. Itzykson R, Gardin C, Pautas C, et al; Acute Leukemia French Association (ALFA). Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica. 2011 Jun;96(6):837-44.Texto completo Resumen
75. Li Z, Liu Y, Wang Q, et al. Autologous stem cell transplantation is a viable postremission therapy for intermediate-risk acute myeloid leukemia in first complete remission in the absence of a matched identical sibling: a meta-analysis. Acta Haematol. 2019;141(3):164-75.Texto completo Resumen
76. Amadori S, Suciu S, Selleslag DJ, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. Clin Oncol. 2016 Mar 20;34(9):972-9.Texto completo Resumen
77. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011 Feb 1;29(4):369-77.Texto completo Resumen
78. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012 Nov 10;30(32):3924-31.Texto completo Resumen
79. Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012 Apr 21;379(9825):1508-16. Resumen
80. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014 Aug;15(9):986-96.Texto completo Resumen
81. Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019 Jan;104(1):113-9.Texto completo Resumen
82. Pollard JA, Guest E, Alonzo TA, et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 2021 Oct 1;39(28):3149-60. Resumen
83. Kapp-Schwoerer S, Weber D, Corbacioglu A, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood. 2020 Dec 24;136(26):3041-50.Texto completo Resumen
84. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 Aug 3;377(5):454-64.Texto completo Resumen
85. Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019 Feb 21;133(8):840-51.Texto completo Resumen
86. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46.Texto completo Resumen
87. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 Sep 10;36(26):2684-92.Texto completo Resumen
88. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul;8(7):e481-91. Resumen
89. Boumber Y, Kantarjian H, Jorgensen J, et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov;26(11):2428-31. Resumen
90. Fenaux P, Mufti G, Santini V, et al. Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens: results of the AZA-001 phase III study. Blood. 2007;110:250a.
91. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):562-9.Texto completo Resumen
92. Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):556-61.Texto completo Resumen
93. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7.Texto completo Resumen
94. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9.Texto completo Resumen
95. Short NJ, Kantarjian HM, Loghavi S, et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan;6(1):e29-e37.Texto completo Resumen
96. Bell JA, Galaznik A, Huelin R, et al. Effectiveness and safety of therapeutic regimens for elderly patients with acute myeloid leukemia: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e303-14.Texto completo Resumen
97. Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020 Dec 24;383(26):2526-37.Texto completo Resumen
98. Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019 May 20;37(15):1277-84.Texto completo Resumen
99. Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020 Jun 11;135(24):2137-45.Texto completo Resumen
100. DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 Feb;19(2):216-28. Resumen
101. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 Jan 3;133(1):7-17.Texto completo Resumen
102. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13;383(7):617-29.Texto completo Resumen
103. Medicines and Healthcare Products Regulatory Agency. Venetoclax (Venclyxto): updated recommendations on tumour lysis syndrome (TLS). Dec 2021 [internet publication].Texto completo
104. Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 Feb;33(2):379-89.Texto completo Resumen
105. Cortes JE, Heidel FH, Fiedler W, et al. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020 Jul 14;13(1):92.Texto completo Resumen
106. Heuser M, Smith BD, Fiedler W, et al. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021 May;100(5):1181-94.Texto completo Resumen
107. Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Feb 13;135(7):463-71.Texto completo Resumen
108. Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022 Apr 21;386(16):1519-31.Texto completo Resumen
109. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-31. Resumen
110. Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019 Nov;33(11):2575-84.Texto completo Resumen
111. Food and Drug Administration. FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib). Nov 2018 [internet publication].Texto completo
112. Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021 Dec 30;138(26):2753-67.Texto completo Resumen
113. DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020 Aug 27;136(9):1023-32.Texto completo Resumen
114. Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, et al. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018 Jul;97(7):1115-53. Resumen
115. Stahl M, DeVeaux M, Montesinos P, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 Apr 24;2(8):923-32.Texto completo Resumen
116. Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018 Sep;103(9):e404-7.Texto completo Resumen
117. DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 Mar;93(3):401-7.Texto completo Resumen
118. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019 Oct 31;381(18):1728-40.Texto completo Resumen
119. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386-98.Texto completo Resumen
120. Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023 Jan;10(1):e46-58. Resumen
121. de Botton S, Fenaux P, Yee KWL, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023 Feb 1:bloodadvances.202200941.Texto completo Resumen
122. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007 Jan;21(1):66-71. Resumen
123. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005 Mar 20;23(9):1969-78.Texto completo Resumen
124. Yanada M, Garcia-Manero G, Borthakur G, et al. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer. 2007 Dec 15;110(12):2756-60.Texto completo Resumen
125. Wattad M, Weber D, Döhner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017 Jun;31(6):1306-13. Resumen
126. Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-43.Texto completo Resumen
127. Lo-Coco F, Avvisati G, Vignetti M, et al; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21.Texto completo Resumen
128. Burnett AK, Russell NH, Hills RK, et al.; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1295-305. Resumen
129. Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017 Feb 20;35(6):605-12. Resumen
130. Zhu H, Hu J, Li X, et al. All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis. Br J Haematol. 2015 Oct;171(2):277-80.Texto completo Resumen
131. Cicconi L, Platzbecker U, Avvisati G, et al. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. 2020 Mar;34(3):914-8. Resumen
132. Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84.Texto completo Resumen
133. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46.Texto completo Resumen
134. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7.Texto completo Resumen
135. Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80; quiz 1752.Texto completo Resumen
136. Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015 Sep;2(9):e357-66. Resumen
137. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 28;116(17):3171-9.Texto completo Resumen
138. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999 Aug 15;94(4):1192-200.Texto completo Resumen
139. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocyticleukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25.Texto completo Resumen
140. Muchtar E, Vidal L, Ram R, et al. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD009594.Texto completo Resumen
141. Cicconi L, Breccia M, Franceschini L, et al. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Ann Hematol. 2018 Oct;97(10):1797-802. Resumen
142. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474.Texto completo Resumen
143. Stanworth SJ, Estcourt LJ, Powter G, et al; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013 May 9;368(19):1771-80.Texto completo Resumen
144. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001 May 15;97(10):2998-3003.Texto completo Resumen
145. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 Oct 20;36(30):3043-54.Texto completo Resumen
146. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012 Jul 10;30(20):2441-8.Texto completo Resumen
147. Pluta A, Robak T, Wrzesien-Kus A, et al. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Am J Hematol. 2017 Apr;92(4):359-66.Texto completo Resumen
148. ClinicalTrials.gov. Cladribine; acute myeloid leukemia; phase 3 [internet publication].Texto completo
149. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 6;121(23):4655-62.Texto completo Resumen
150. Ohanian M, Garcia-Manero G, Levis M, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018 Sep;93(9):1136-41.Texto completo Resumen
151. Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1201-12. Resumen
152. Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 May 13;401(10388):1571-83. Resumen
153. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):984-97. Resumen
154. Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia. J Hematol Oncol. 2017 Apr 18;10(1):93.Texto completo Resumen
155. Roboz GJ, Döhner H, Gobbi M, et al. Results from a global randomized phase 3 study of guadecitabine (G) vs treatment choice (TC) in 815 patients with treatment naïve (TN) AML unfit for intensive chemotherapy (IC) ASTRAL-1 study: analysis by number of cycles. Blood 2019 Nov;134(1 suppl):2591.
156. ClinicalTrials.gov. Guadecitabine; acute myeloid leukemia; phase 2 [internet publication].Texto completo
157. Rubnitz JE, Lacayo NJ, Inaba H, et al. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial. J Clin Oncol. 2019 Aug 10;37(23):2072-81.Texto completo Resumen
158. Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013 Aug 22;122(8):1384-94.Texto completo Resumen
159. ClinicalTrials.gov. Crenolanib; acute myeloid leukemia; phase 3 [internet publication].Texto completo
160. ClinicalTrials.gov. Flotetuzumab; acute myeloid leukemia; phase 2 [internet publication].Texto completo
161. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. Resumen
162. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. Resumen
163. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER*Explorer [internet publication].Texto completo
164. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997 May 1;89(9):3323-9.Texto completo Resumen
165. Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015 Jan 29;125(5):767-74.Texto completo Resumen
166. Rausch C, Rothenberg-Thurley M, Dufour A, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 11 Apr 2023 [Epub ahead of print].Texto completo Resumen
167. Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009 Jun 1;27(16):2668-76. Resumen
168. Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):357-62.Texto completo Resumen
169. Gribben JG. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020 Mar;188(6):844-51.Texto completo Resumen
170. Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD008238. Resumen
171. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010 Jun 10;28(17):2914-24. Resumen
172. Deak D, Gorcea-Andronic N, Sas V, et al. A narrative review of central nervous system involvement in acute leukemias. Ann Transl Med. 2021 Jan;9(1):68.Texto completo Resumen
173. Norsworthy KJ, Mulkey F, Scott EC, et al. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis. Clin Cancer Res. 2020 Aug 15;26(16):4280-8.Texto completo Resumen
174. McMahon CM, Canaani J, Rea B, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019 May 28;3(10):1581-5.Texto completo Resumen
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad